Loading
A phase 1/2 trial of IPN01203 in advanced solid tumours, run by Ipsen, now recruiting.
A Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, Immunogenicity and Anti-tumour Activity of IPN01203 in Adults With Locally Advanced or Metastatic Solid Tumours Exposed to Immune Checkpoint Inhibitor Therapies is a phase 1/2 interventional study registered as NCT07213830 by Ipsen, with 102 participants planned, started 2026-02-06 and due to reach its primary completion in 2032-07-14. Interventions recorded: IPN01203.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Ipsen, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Ipsen, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Ipsen, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/